ArticleFrontiers in medicine2026
Beyond cartilage degeneration: osteoarthritis as a systems failure of inflammation regulation.
Article in Frontiers in medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Osteoarthritis (OA) is traditionally framed as a degenerative cartilage disease caused by age-related mechanical wear. However, this paradigm does not adequately account for the synovitis, metabolic disturbance, and pain that commonly precede overt structural loss. In this Hypothesis and Theory article, we propose a testable systems model in which OA reflects a failure of interdependent synovial regulatory networks rather than a purely structural endpoint. These networks include: (1) energy-redox imbalance driven by declining NAD+ availability and mitochondrial inefficiency, which may prime synovial inflammation; (2) dysregulated MRP4- and MCT4-dependent efflux, leading to extracellular accumulation of prostaglandins and lactate that may promote nociception and stromal activation; (3) reduced protein phosphatase 2A (PP2A)-mediated signaling restraint, which may permit persistence of NF-κB and MAPK phosphorylation; and (4) impaired lipid mediator class switching, which may limit biosynthesis of specialized pro-resolving mediators such as Maresin-2 and Resolvin D1. We further propose that microtubule organization may function as a mechanometabolic interface linking redox decline, lactate signaling, transporter localization, and impaired mechanosensing. Because current anti-inflammatory therapies largely suppress inflammatory output rather than restore regulatory control, they may provide symptomatic relief without durable disease modification. We therefore outline a regulatory-restoration framework focused on NAD+ -redox alignment, mediator transport, phosphatase tone, and resolution-pathway recovery, while explicitly defining the limitations and falsifiable predictions of the model.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.